☆ 4.4 Review

Immunizing the imperfect immune system Coronavirus disease 2019 vaccination in patients with inborn errors of immunity

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin

Andreas Volk et al.

Summary: Patients with immune deficiencies often receive antibodies from healthy donors as a first line of defense against infections. Research shows that plasma-derived immunoglobulin lots produced between December 2020 and June 2021 have increasing neutralizing activity against SARS-CoV-2 over time.

BIODRUGS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Markus Hoffmann et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.

CELL (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine

Telma Miyuki Oshiro et al.

CLINICS (2022)

Add to Collection

Article Medicine, General & Internal

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

Matthew E. Oster et al.

Summary: Based on reports in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased, especially among adolescent males and young men, particularly after the second dose. This risk should be considered in the context of the benefits of COVID-19 vaccination.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Letter Allergy

Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency

Ane Fernandez Salinas et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Allergy

Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects

Michele N. Pham et al.

Summary: The study assessed the immune responses in patients with PID after receiving COVID-19 mRNA vaccines. It was found that cellular immunity was stimulated in most patients, but antibody responses to the spike protein RBD were inconsistent and ineffective at ACE2 blocking in some cases.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency

Daniel Arroyo-Sanchez et al.

Summary: Common Variable Immunodeficiency (CVID) patients show slower humoral and cellular responses to COVID-19 vaccination compared to healthy controls. Despite most CVID patients developing S1-specific antibodies and T cells after vaccination, neutralizing antibodies were only detected in half of the patients. Those with absent or discordant responses often had a history of autoimmunity or lymphoproliferation, while recent anti-B cell antibody therapy may also weaken the response. Further studies are necessary to assess the protective efficacy of COVID-19 vaccination in CVID patients, with consideration for a third dose to achieve full immune response.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Letter Immunology

Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report

Rachel E. Bradley et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

Dennis M. Bierle et al.

Summary: Breakthrough COVID-19 may occur in fully vaccinated individuals, but monoclonal antibody treatment can reduce the risk of hospitalization, especially in high-risk individuals with medical comorbidities.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

J. Sadoff et al.

Summary: The Ad26.COV2.S vaccine was found to be 52.9% effective against moderate to severe-critical Covid-19 after a single dose, with protection lasting for at least 6 months. Efficacy varied depending on the Covid-19 variant, but higher protection was observed against severe cases, medical intervention, and death compared to other outcomes.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Allergy

Psychological State of Parents of Children with Primary Immunodeficiencies During the COVID-19 Pandemic

Berhan Akdag et al.

Summary: COVID-19 has led to anxiety and post-traumatic stress in parents of children with primary immunodeficiency, affecting their sleep quality and duration. Providing professional support to these parents is crucial during pandemics.

PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY (2022)

Add to Collection

Article Immunology

Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination

Kai M. T. Sauerwein et al.

Summary: Previous studies have shown inconclusive results about the ability of patients with common variable immunodeficiency (CVID) to produce vaccine-specific IgG antibodies following COVID-19 vaccination. This study aimed to investigate the immune responses in patients with CVID and milder forms of primary antibody deficiency after receiving the BNT162b2 vaccine. The results demonstrated that normal IgG responses were associated with intact vaccine-specific activation of CXCR5-negative CD4(+) memory T cells in patients with CVID and other milder forms of antibody deficiency. However, defective activation of circulating T follicular helper cells was observed. Impaired TCR-mediated activation of CXCR5-negative CD4(+) memory T cells following vaccination identified patients with primary antibody deficiency and impaired IgG responses.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Allergy

Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses

Elif Karakoc Aydiner et al.

Summary: In this study, 34 IEI patients were evaluated for SARS-CoV-2 infection outcomes, with combined immune deficiency (CID) and immune dysregulation (ID) patients being more susceptible to COVID-19 mortality. Laboratory markers at admission, such as high CRP and low lymphocyte count, were found to predict patients' risk of death.

ALLERGY (2022)

Add to Collection

Review Allergy

Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients

Yvelise Barrios et al.

Summary: This study validates the use of cutaneous delayed-type hypersensitivity (DTH) to assess cellular immune response (CIR) and shows a good correlation with ex vivo CIR. The evaluation of CIR after COVID vaccination in patients with antibody deficiencies has high precision and is more sensitive than antibody-based methods in Common Variable Immunodeficiency (CVID). The implementation of a COVID-specific skin DTH test could be clinically impactful for large populations.

ALLERGOLOGIA ET IMMUNOPATHOLOGIA (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Anil Gupta et al.

Summary: The study showed that sotrovimab treatment significantly reduced the risk of all-cause hospitalization or death in nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression. Sotrovimab also decreased the risk of emergency department visits, hospitalization, or death, as well as the progression to severe or critical respiratory COVID-19. Adverse events were similar between the treatment and placebo groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Allergy

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity

Leanne P. M. van Leeuwen et al.

Summary: This study evaluated the immune response of COVID-19 vaccines in patients with IEI. The results showed that COVID-19 vaccination was immunogenic in patients with mild antibody deficiencies and phagocyte defects, but had lower immunogenicity in patients with more severe IEI like CVID and combined B- and T-cell immunodeficiency. The presence of noninfectious complications and the use of immunosuppressive drugs negatively affected the antibody response in patients with CVID.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Letter Allergy

The arrival of SARS-CoV-2-neutralizing antibodies in a currently avail- able commercial immunoglobulin

Aaron L. Miller et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients

Hagai Ligumsky et al.

Summary: The study found that solid tumor patients had lower antibody titers and a lower proportion of seropositive patients compared to healthy individuals, especially among chemotherapy-treated patients. The BNT162b2 vaccine was safe and well-tolerated in these patients, with no severe side effects reported. Continued use of personal protective measures is recommended for this population even after vaccination.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Immunology

SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine

Sudhir Gupta et al.

Summary: This study evaluated the T cell response to COVID-19 infection and vaccination in patients with primary antibody deficiencies. The results showed that COVID-19 infection led to higher levels of SARS-CoV-2-specific CD8 and functional CTLs in a patient with XLA, while in CVID patients, both natural infection and vaccination resulted in lower levels of these cells.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Cell Biology

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Kathryn Westendorf et al.

Summary: A monoclonal antibody named LY-CoV1404 has been successfully isolated, which demonstrates highly potent neutralization against multiple variants of the SARS-CoV-2 virus. The binding site of LY-CoV1404 remains relatively conserved, allowing it to maintain its activity. This finding suggests that LY-CoV1404 has the potential to be an effective therapeutic agent against all known variants.

CELL REPORTS (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review

Edward P K Parker et al.

Lancet Global Health (2022)

Add to Collection

Article Immunology

Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy

Arnau Antoli et al.

Summary: The study found that SARS-CoV-2 vaccines are less effective in CVID phenotype and BCD patients compared to healthy individuals. Predictive factors of inadequate specific antibody response in CVID phenotype patients include low IgA values, low CD19+ peripheral B cells, low switched memory B cells, and a low CD4+/CD8+ ratio. Further studies are needed to understand the effectiveness of vaccines in immunocompromised patients and predictive factors of immune response failure.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Allergy

Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency

Sara Barmettler et al.

Summary: Patients with predominant antibody deficiency (PAD) who receive SARS-CoV-2 immunization show a lower antibody response, but there is improvement after receiving an additional dose of the vaccine.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection

Article Immunology

Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency

Vera Goda et al.

Summary: This study evaluated the immune response of CVID patients receiving booster vaccination with BNT162b2 against SARS-CoV-2. The results showed that the vaccine can increase antibody levels and T cell response in CVID patients, but the response levels are still lower compared to healthy individuals.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Living with primary immunodeficiency disease during the Covid-19 pandemic

Kerri L. Sowers et al.

Summary: Patients with PID have shown extreme caution during the COVID-19 pandemic, minimizing their exposure risk while expressing hopes of returning to normal activities with widespread herd immunity, an effective vaccine, or public health protections. However, they also have significant concerns about additional waves of COVID-19 cases as their state or country reopens.

JOURNAL OF PUBLIC HEALTH-HEIDELBERG (2022)

Add to Collection

Article Allergy

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

Isabelle Meyts et al.

Summary: The study shows that patients with IEI exhibit varied responses to SARS-CoV-2 infection, with some requiring hospitalization and even intensive care, and a non-negligible mortality rate. In comparison to the general population, younger IEI patients may face a higher risk of severe illness and mortality.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Allergy

Severe SARS-CoV-2 disease in the context of a NF-κB2 loss-of-function pathogenic variant

Roshini S. Abraham et al.

Summary: COVID-19, caused by SARS-CoV-2, can have a significant impact on the immune system. This study evaluated a novel NFKB2 loss of function variant in a 17-year-old male patient and discussed the clinical management of SARS-CoV-2 infection in this context. Despite underlying immune dysfunction, the patient recovered from the infection with intense management.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Allergy

Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City

Hsi-en Ho et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Hematology

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Andreas Greinacher et al.

Summary: The mechanism underlying vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily involves the formation of PF4/vaccine complexes and the proinflammatory environment stimulated by the vaccine, leading to the production of high-titer anti-PF4 antibodies in the body and consequent thrombosis.

BLOOD (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States

Yousaf Bashir Hadi et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Immunology

SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best

Ane Fernandez Salinas et al.

Summary: After BNT162b2 vaccination, some patients with primary antibody deficiencies exhibited atypical immune responses, possibly due to extra-follicular reactions or incomplete germinal center reactions. It remains unknown whether these responses to the vaccine might provide partial protection from infection or reinfection.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

Ann R. Falsey et al.

Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Ai-ris Y. Collier et al.

Summary: The kinetics of immune response to Covid-19 vaccines were studied, showing varying peak levels and durations of response for different vaccines. However, the response levels correlating with protection have not been defined yet.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp et al.

Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.

NATURE (2021)

Add to Collection

Article Immunology

Seroconversion Following COVID-19 Vaccination in Immune Deficient Patients

Jacqueline Squire et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019

Ghady Haidar et al.

Summary: Recent case studies have shown that immunocompromised individuals are at risk for prolonged SARS-CoV-2 replication, viral evolution, and poor clinical outcomes. The immunologic determinants of this risk, optimal treatment strategies, and use of immunosuppressive medications for COVID-19 in immunocompromised hosts are not well understood. Studies are needed to better understand these factors and improve management of these patients.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies

Donato Amodio et al.

Summary: The study analyzed the immune response following the BNT162b2 mRNA COVID-19 vaccine in immunocompromised patients compared to healthy controls. It found that some immunocompromised patients did not develop specific CD4+CD40L+ T cell responses, indicating the importance of evaluating T cell immune responses in this subpopulation.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

CD19+IgD+CD27-Naive B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients

Eduard Schulz et al.

Summary: In immunocompromised patients, the number of naive B cells correlates strongly with antibody levels post COVID-19 vaccination, serving as the key predictor for achieving a humoral response comparable to healthy individuals.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge

Anna Furlan et al.

Summary: The study demonstrates significant effects of B cell-depleting agents on adaptive immunity, which should be considered in the selection of SARS-CoV-2 diagnostics and guiding therapeutic approaches. Combination therapeutic strategies may play a crucial role in the setting of B cell immune deficiencies.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Peter Bergman et al.

Summary: This prospective clinical trial investigated the safety and efficacy of the BNT162b2 mRNA vaccine in immunocompromised patients and healthy controls. The vaccine was found to be safe in immunocompromised patients, but with a lower seroconversion rate compared to healthy controls. Additional vaccine doses may be needed to improve immunity in certain immunocompromised patient groups.

EBIOMEDICINE (2021)

Add to Collection

Article Cell Biology

B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies

Federica Pulvirenti et al.

Summary: The study reveals that SARS-CoV-2 infection induces spike-specific IgG production more frequently in CVID patients compared to vaccination, with convalescents showing boosted antibody response after vaccination. Vaccination leads to atypical memory B cell responses, while spike-specific memory B cells generated after infection can be improved by subsequent immunization.

CELLS (2021)

Add to Collection

Article Immunology

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency

Hannah Kinoshita et al.

Summary: This study characterized antibody and T cell responses to SARS-CoV-2 structural proteins in patients with antibody deficiencies, showing robust T cell activity and humoral immunity in some patients. The study results are encouraging, especially considering the reliance on spike protein in most candidate vaccines, but further research is needed to define the timing of immunity onset, longevity of immune response, and variability in immunocompromised patients.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Paul Bastard et al.

Summary: Patients with biallelic loss-of-function variants of AIRE, suffering from APS-1, produce autoantibodies that neutralize most type I interferons, leading to a significantly increased risk of life-threatening COVID-19 pneumonia. Research has shown that in APS-1 patients with these neutralizing autoantibodies, 86% developed COVID-19 pneumonia.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Review Immunology

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

Giuseppe A. Ramirez et al.

Summary: Aberrant deployment of the immune response is a key feature of COVID-19, with vaccination against SARS-CoV-2 being effective and safe for patients with immune-mediated diseases. However, tailored strategies are needed for these patients to optimize vaccination outcomes, especially for those with primary immunodeficiencies. Additional data is necessary for this specific patient population to further understand the impact of vaccination.

VACCINES (2021)

Add to Collection

Editorial Material Multidisciplinary Sciences

The emerging plasticity of SARS-CoV-2

Kevin D. McCormick et al.

SCIENCE (2021)

Add to Collection

Article Immunology

Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination

Nizar Abo-helo et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign

Amir Ben-Tov et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Allergy

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

David Hagin et al.

Summary: The study evaluated the humoral and cellular immune response to the COVID-19 vaccine in patients with IEI, finding that most patients were able to develop vaccine-specific antibody response and S-protein-specific cellular response, and no significant adverse events were reported during the vaccination process.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Allergy

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity

Ottavia M. Delmonte et al.

Summary: The study evaluated antibody response and adverse events in IEI patients after COVID-19 vaccination, finding that vaccination is safe but immunogenicity is affected by certain therapies and gene defects. This data can guide counseling of IEI patients on preventing SARS-CoV-2 infection and the need for subsequent boosts.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Immunology

Safety of COVID-19 Vaccination in Immune-Deficient Patients Receiving Supplemental Immunoglobulin Therapies

Jacqueline D. Squire et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins

Michael Karbiener et al.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

C. R. Simpson et al.

Summary: Analysis of data from the EAVE II cohort in Scotland has shown that a first dose of the ChAdOx1 nCoV-19 vaccine may be associated with increased risks of idiopathic thrombocytopenic purpura, arterial thromboembolic events, and hemorrhagic events. However, there were no positive associations found between the BNT162b2 vaccine and these adverse events.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

H. M. El Sahly et al.

Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Rheumatology

Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis

Lars Erik Bartels et al.

Summary: The study investigates the safety and reactogenicity of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine among patients with SLE and RA. Most patients experienced either local or systemic reactions within seven days after vaccination, with severe reactions being rare.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

Add to Collection

Article Immunology

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients

Elise M. N. Ferre et al.

Summary: Treatment with bamlanivimab and etesevimab in APECED patients may have potential benefits, as early administration can improve COVID-19 symptoms and prevent disease progression, without affecting the production of antibodies to the nucleocapsid protein of SARS-CoV-2.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy

Stacey Schultz-Cherry et al.

Summary: The study found that receiving COVID-19 vaccination shortly after COVID-19-specific monoclonal antibody therapy can enhance and broaden antibody protection, questioning the necessity of delaying vaccination in this scenario.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Economics

Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

Manuela Di Fusco et al.

Summary: This study evaluates COVID-19 vaccine breakthrough infections among immunocompromised individuals, showing that breakthrough infections are more common and severe in this population, with a higher hospitalization and mortality rate compared to non-immunocompromised individuals. The findings support the FDA authorization and CDC recommendations for a third vaccine dose to increase protection among immunocompromised individuals.

JOURNAL OF MEDICAL ECONOMICS (2021)

Add to Collection

Article Otorhinolaryngology

Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in MAGTI Deficiency

Maaz Jalil et al.

Summary: The study reports a successful response to anti-SARS-CoV-2 spike protein antibodies post-vaccination in a patient with MAGT1 deficiency, suggesting the safety and efficacy of COVID-19 vaccination in immunodeficient patients, although larger scale studies are needed for confirmation.

ALLERGY & RHINOLOGY (2021)

Add to Collection

Article Otorhinolaryngology

The Successful Vaccination of an IVIgG Naive CVID Patient with an mRNA COVID-19 Vaccine

Maaz Jalil et al.

Summary: This case report discusses a 78-year-old female with Common Variable Immunodeficiency who responded positively to a COVID-19 mRNA vaccine despite being IVIgG naive. The patient successfully developed COVID-19 spike protein IgG antibodies after vaccination, demonstrating the ability of immunodeficient patients to mount an immune response to certain vaccines.

ALLERGY & RHINOLOGY (2021)

Add to Collection

Editorial Material Oncology

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Wenhua Liang et al.

LANCET ONCOLOGY (2020)

Add to Collection

Article Allergy

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Isabella Quinti et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Correction Multidisciplinary Sciences

A human monoclonal antibody blocking SARS-CoV-2 infection (vol 11, 2251, 2020)

Chunyan Wang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Oncology

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Mengyuan Dai et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Allergy

Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency

David Friedmann et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Allergy

Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance the COVID-19 Pandemic

Federica Pulvirenti et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

Add to Collection

Article Immunology

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

Baldassarre Martire et al.

VACCINE (2018)

Add to Collection

Article Immunology

Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency

Leif G. Hanitsch et al.

VACCINE (2016)

Add to Collection

Article Allergy

Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts

William T. Shearer et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

Add to Collection

Article Immunology

Dendritic and T Cell Response to Influenza is Normal in the Patients with X-Linked Agammaglobulinemia

Yinping Liu et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.